Related Experiment Video
Updated: Aug 26, 2025

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
Published on: May 14, 2012
[Development of antigen-receptor modified allogeneic T cell from iPS cells for cancer immunotherapy]
Shin Kaneko1,2
1Laboratory of Regenerative Immunotherapy, CiRA, Kyoto University.
Abstract:
The efficacy of T-cell therapy depends on the maintenance of antigen specificity, memory phenotype, longterm viability, and proliferative capacity of T cells in vivo. Personalized autologous T-cell therapies pose a few manufacturing challenges, in terms of quality, and supply stability. Recently, it has become possible to derive CD8 killer T cells from induced pluripotent stem cells (iPSCs) and develop CAR-CD8 killer T cells from allogeneic iPSCs. This article reviews CD8 killer T-cell induction from iPSCs, attempts to enhance process safety and reliability, and discusses the use of gene-editing technology for reducing allogeneic antigenicity.
Related Concept Videos
iPS Cell Differentiation
Induced Pluripotent Stem Cells
Somatic...
EPS and iPS Cells in Disease Research
Somatic to iPS Cell Reprogramming
Tumor Immunotherapy

